Mineralys Therapeutics (MLYS) Cash from Operations (2022 - 2026)

Mineralys Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 39471000.0 in Q1 2026.

• Quarterly Cash from Operations rose 13.23% year-over-year to 39471000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 136400000.0 (up 29.2% YoY) and the FY2025 annual result came in at 142416000.0, up 14.37% from the prior year.
• Cash from Operations fell to 39471000.0 in Q1 2026 per MLYS's latest filing, from 37916000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 5469000.0 in Q2 2022 and troughed at 66843000.0 in Q4 2024.
• A 5-year average of 26976176.47 and a median of 28800000.0 in 2025 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 272.76% in 2023, then soared 43.28% in 2025.
• Over 5 years, Cash from Operations stood at 10186000.0 in 2022, then slumped by 184.52% to 28981000.0 in 2023, then slumped by 130.64% to 66843000.0 in 2024, then jumped by 43.28% to 37916000.0 in 2025, then dropped by 4.1% to 39471000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 39471000.0, 37916000.0, and 28800000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.